EP1225907A4 - Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques - Google Patents

Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques

Info

Publication number
EP1225907A4
EP1225907A4 EP00972031A EP00972031A EP1225907A4 EP 1225907 A4 EP1225907 A4 EP 1225907A4 EP 00972031 A EP00972031 A EP 00972031A EP 00972031 A EP00972031 A EP 00972031A EP 1225907 A4 EP1225907 A4 EP 1225907A4
Authority
EP
European Patent Office
Prior art keywords
immunodic
hiv
virus
peptide
induction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00972031A
Other languages
German (de)
English (en)
Other versions
EP1225907A1 (fr
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Brian D Livingston
Robert Chesnut
Denise Marie Baker
Esteban Celis
Ralph T Kubo
Howard M Grey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1225907A1 publication Critical patent/EP1225907A1/fr
Publication of EP1225907A4 publication Critical patent/EP1225907A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP00972031A 1999-10-05 2000-10-05 Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques Withdrawn EP1225907A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41286399A 1999-10-05 1999-10-05
US412863 1999-10-05
PCT/US2000/027766 WO2001024810A1 (fr) 1999-10-05 2000-10-05 Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques

Publications (2)

Publication Number Publication Date
EP1225907A1 EP1225907A1 (fr) 2002-07-31
EP1225907A4 true EP1225907A4 (fr) 2005-06-22

Family

ID=23634801

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00972031A Withdrawn EP1225907A4 (fr) 1999-10-05 2000-10-05 Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques

Country Status (5)

Country Link
EP (1) EP1225907A4 (fr)
JP (1) JP4873810B2 (fr)
AU (1) AU1075001A (fr)
CA (1) CA2386499A1 (fr)
WO (1) WO2001024810A1 (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7790171B1 (en) 2000-08-25 2010-09-07 Centre National De La Recherche Scientifique (C.N.R.S.) Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase
FR2824326B1 (fr) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications
ES2274100T3 (es) * 2001-09-07 2007-05-16 Polymun Scientific Immunbiologische Forschung Gmbh Anticuerpos que reconocen a un peptido que imita a un epitopo criptico de gp41 del vih-1.
CA2357906A1 (fr) * 2001-09-28 2003-03-28 Institut Pasteur Identification de nouveaux epitopes de cd8 de proteines ayant des proprietes therapeutiques et immunologiques pour lutter contre les infections a vih
KR20040040475A (ko) * 2001-09-28 2004-05-12 가부시키가이샤 디나벡크 겐큐쇼 에피토프 결합 β２ｍ을 코드하는 포유동물 세포감염성 바이러스 벡터 및 그의 이용
ES2605445T3 (es) * 2001-11-26 2017-03-14 Hivih Interacciones proteína-proteína en el virus de la inmunodeficiencia humana
AU2003207835A1 (en) * 2002-02-04 2003-09-02 Auburn University Peptides for recognition and targeting of glial cell tumors
EP1431306A1 (fr) * 2002-12-19 2004-06-23 Creabilis Therapeutics s.r.l. Mécanisme de la pénétration du VIH dans les cellules hôtes et peptides pour inhiber ce mécanisme
CA2497890A1 (fr) * 2002-09-13 2004-03-25 Creabilis Therapeutics S.P.A. Nouveau mecanisme d'entree du vih-1 dans des cellules hotes et peptides inhibant ce mecanisme
ATE520708T1 (de) 2003-03-28 2011-09-15 Us Gov Health & Human Serv Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
WO2004106365A2 (fr) * 2003-05-28 2004-12-09 Aventis Pasteur, Inc. Motifs modulateurs destines a induire une reponse immunitaire de type th1 ou th2
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US20050112139A1 (en) * 2003-10-23 2005-05-26 Nmk Research, Llc Immunogenic composition and method of developing a vaccine based on factor H binding sites
EP1697399B1 (fr) * 2003-12-12 2016-11-23 GOVERNMENT OF THE UNITED STATES OF AMERICA, as repr. by THE SECR. OF THE DEPT. OF HEALTH AND HUMAN SERVICES AND HIS SUCCESSORS Epitope de lymphocyte t cytotoxique humain et son epitope agoniste issus du nombre non variable de sequences repetees en tandem de muc-1
WO2005116055A1 (fr) * 2004-05-24 2005-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptides, anticorps et compositions contenant ceux-ci, utilises pour traiter une infection provoquee par le virus vih
FR2874612A1 (fr) * 2004-08-27 2006-03-03 Commissariat Energie Atomique Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications
US8029797B2 (en) 2005-03-01 2011-10-04 Variation Biotechnologies Inc. Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions
US7501398B2 (en) * 2005-07-22 2009-03-10 Universita'degli Studi Di Milano Inhibitor of the folding of the HIV-1-protease as antiviral agent
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
ES2616341T3 (es) * 2006-03-10 2017-06-12 Peptcell Limited Péptidos de proteínas reguladoras o accesorias de VIH, composiciones y la utilización de las mismas
DE602007010127D1 (en) * 2006-06-01 2010-12-09 Statens Seruminstitut Hiv-impfstoff
WO2008068765A2 (fr) * 2006-12-07 2008-06-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions et procédés pour inhiber la réplication du vih-1 et l'activité de l'intégrase
EA017887B1 (ru) 2007-08-02 2013-03-29 Байондвакс Фармасьютикалз Лтд. Полимерные мультиэпитопные вакцины против гриппа
JP2010536885A (ja) * 2007-08-24 2010-12-02 ノバルティス アーゲー Ｖ３ループに改変を有するｈｉｖｅｎｖタンパク質
WO2009043155A2 (fr) * 2007-10-03 2009-04-09 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Epitopes gag et env distincts du vih-1 d'allèles du système hla associés à une réceptivité différente à l'infection par le vih-1
WO2010011343A2 (fr) * 2008-07-25 2010-01-28 The Regents Of The University Of Colorado Procédés de traitement d’affections virales
WO2010041241A2 (fr) 2008-10-06 2010-04-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Peptides dérivés de l'intégrase du vih-1 et compositions
EP2391635B1 (fr) 2009-01-28 2017-04-26 Epimmune Inc. Polypeptides de liaison de pan-dr et leurs utilisations
WO2011008863A2 (fr) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Peptides stéréoisomères et leurs conjugués polymères pour infection par le vih
ES2358829B1 (es) 2009-10-23 2012-06-25 Lipotec, S.A. Péptidos útiles en el tratamiento y/o cuidado de la piel, mucosas y/o cabello y su uso en composiciones cosméticas o farmacéuticas.
CA2817418A1 (fr) * 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Sequences hautement immunogenes de la proteine p24 du vih
EP2452947A1 (fr) 2010-11-16 2012-05-16 Münch, Jan Peptide augmentant l'infection virale
WO2012114323A1 (fr) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Polypeptides multimères multi-épitopes utilisés dans des vaccins contre la grippe saisonnière et pandémique
CA2833425C (fr) * 2011-04-07 2018-08-21 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Peptides de site de clivage de protease comme vaccin contre le vih
US9327009B2 (en) * 2012-03-02 2016-05-03 Council Of Scientific And Industrial Research Peptide inhibitors as novel anti-HIV therapeutics
EP2745845A1 (fr) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux Procédé de prévention ou de traitement d'une infection par VIH
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
KR101476255B1 (ko) * 2014-02-07 2014-12-26 대한민국 HIV-l 유래 T 세포 항원결정기를 갖는 재조합 펩타이드 및 이를 포함하는 백신 조성물
ES2959642T3 (es) * 2015-05-13 2024-02-27 The Us Secretary Of The Department Of Health And Human Services Metodos y composiciones para inducir una respuesta inmunitaria mediante construcciones con elementos conservados
CA3045756A1 (fr) 2015-12-05 2017-06-08 Centre Hospitalier Universitaire Vaudois Agents de liaison au vih
GB2549798A (en) * 2016-04-29 2017-11-01 Univ Bradford Peptides and nanoparticle formulations thereof
WO2018067582A2 (fr) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes de peptides de fusion env du vih-1 et leur utilisation
WO2020092705A1 (fr) * 2018-10-31 2020-05-07 University Of Virginia Patent Foundation Peptides et hydrogels à auto-assemblage
IT202000019708A1 (it) * 2020-08-07 2022-02-07 Ospedale Pediatrico Bambino Gesù Peptidi in grado di legare il recettore enzima di conversione dell'angiotensina 2 (ACE2) e loro usi medici
CA3192758A1 (fr) * 2020-09-04 2022-03-10 Dompe' Farmaceutici Spa Peptides pourvus d'une activite angiogenique

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
WO1992022577A1 (fr) * 1991-06-17 1992-12-23 Neovacs Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant
WO1997034617A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de liaison aux hla et utilisations
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
WO1999049893A1 (fr) * 1998-03-31 1999-10-07 Trustees Of Boston University Conception de conjugues moleculaires et compositions utilisant de tels conjugues

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2220939B (en) * 1988-06-10 1992-02-26 Medical Res Council Peptide fragments of hiv and their use in vaccines and diagnosis
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
BR9406652A (pt) * 1993-03-05 1996-09-10 Cytel Corp Composição
EP0728764A4 (fr) * 1993-10-19 1999-01-20 Ajinomoto Kk Peptide pouvant induire une reponse immune contre vih et agent contenant ce peptide pour la prevention ou le traitement du sida
WO1997034621A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de fixation de hla-a2.1 et leurs utilisations
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
WO1992022577A1 (fr) * 1991-06-17 1992-12-23 Neovacs Composes immunogenes a effet notamment anti-cytokine, procede de preparation, compositions pharmaceutiques et kits les renfermant
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
WO1997034617A1 (fr) * 1996-03-21 1997-09-25 Cytel Corporation Peptides de liaison aux hla et utilisations
WO1999049893A1 (fr) * 1998-03-31 1999-10-07 Trustees Of Boston University Conception de conjugues moleculaires et compositions utilisant de tels conjugues

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GSP 11 August 1998 (1998-08-11), retrieved from EBI Database accession no. AAW43064 *
DATABASE GSP 12 May 1993 (1993-05-12), retrieved from EBI Database accession no. AAR30963 *
DATABASE GSP 21 February 1990 (1990-02-21), retrieved from EBI Database accession no. AAP90212 *
See also references of WO0124810A1 *

Also Published As

Publication number Publication date
JP2003510099A (ja) 2003-03-18
AU1075001A (en) 2001-05-10
JP4873810B2 (ja) 2012-02-08
CA2386499A1 (fr) 2001-04-12
EP1225907A1 (fr) 2002-07-31
WO2001024810A1 (fr) 2001-04-12

Similar Documents

Publication Publication Date Title
EP1225907A4 (fr) Induction de reponses immunitaires cellulaires au virus de l'immunodeficience humaine de type 1 a l'aide de compositions de peptides et d'acides nucleiques
ID30380A (id) Penghambatan infeksi virus menggunakan protein pengikat antigen bervalensi tunggal
EP1244465A4 (fr) Induction de reponses immunitaires cellulaires aux antigenes du cancer de la prostate au moyen de compositions de peptides et d'acides nucleiques
EP1732598A4 (fr) Induction de reponses immunitaires cellulaires au papillomavirus humain utilisant des compositions peptidiques et d'acides nucleiques
FR16C1012I2 (fr) Utilisation therapeutique d'anticorps anti-cs1
DE60324178D1 (de) THIAZOLIDIN-4-ONES UM hYAK3 PROTEINEN ZU HEMMEN
ATE413188T1 (de) Menschliche papillomavirus impfstoff- formulierungen
DE60138146D1 (de) Frühdiagnose von konformationellen Erkrankungen
EA200000274A3 (ru) Способы получения и промежуточные соединения для получения противораковых соединений
DK1210113T3 (da) Kombinerede vaccinepræparater
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
ATE447947T1 (de) Pharmazeutische zubereitungen zur behandlung von insulinresitenz
EP1246644A4 (fr) Reponse immunitaire cellulaire au papillomavirus humain induite par utilisation de compositions peptidiques et d'acide nucleique
EP1547588A4 (fr) Preparation de capsule molle
DE50014699D1 (de) Medizinisches Instrument zum Präparieren von Gewebe
DE60223841D1 (de) Medizinische verwendung von gsk3-hemmenden oxindolderivaten
PT1119557E (pt) Derivados de indeno- nafto- e benzociclohepta-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorecticos
ATE279193T1 (de) Pharmazeutische zubereitung von moxifloxacin
NO20041802L (no) Antistoffer mot human vevsfaktor
EP1063592A4 (fr) Processeur de documents
EP1460900A4 (fr) Proteines humaines secretees
EP1185545A4 (fr) Proteines d'enveloppe de vih independantes de cd4, utilisees comme vaccins et agents therapeutiques
EP1425039A4 (fr) Peptides immunoreactifs du papillomavirus humain
EP1416957A4 (fr) Traitement de troubles concernant les cellules immunitaires et les cellules b

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020502

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: CELIS, ESTEBAN

Inventor name: KUBO, RALPH, T.

Inventor name: SETTE, ALESSANDRO

Inventor name: LIVINGSTON, BRIAN, D.

Inventor name: SOUTHWOOD, SCOTT

Inventor name: CHESNUT, ROBERT

Inventor name: SIDNEY, JOHN

Inventor name: BAKER, DENISE, MARIE

A4 Supplementary search report drawn up and despatched

Effective date: 20050506

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071201